A new post hoc analysis of a long-term atogepant extension study is turning heads — not just for what the drug does to migraines, but for what it does to the scale. Researchers examined 279 adults with episodic or chronic migraine and a BMI of 25 or higher, tracking weight changes over 52 weeks of daily atogepant 60 mg use. The results, originally presented at the American Academy of Neurology 2026 Annual Meeting and now published in Headache, suggest a meaningful and sustained weight-loss signal.

Weight loss kicked in fast — patients shed an average of about 2 lbs within the first 4 weeks — and continued in a gradual, cyclical pattern of plateaus followed by renewed decline throughout the year. Importantly, the effect didn't appear to be a byproduct of GI side effects like nausea or constipation, which were transient and didn't correlate with weight change, pointing instead to a possible CGRP pathway effect on appetite and metabolism.

By the Numbers

• ~30% of patients lost ≥5% of baseline body weight by week 52
• ~13% lost ≥10% of baseline body weight
• Average weight loss of ~2 lbs within the first 4 weeks
• 279 adults with BMI ≥25 included in the analysis

Why it matters: Obesity and migraine have a bidirectional relationship — excess weight worsens attacks, and migraine disrupts the routines that support healthy weight. While atogepant shouldn't be prescribed solely for weight loss, clinicians can reasonably factor in a patient's weight and cardiovascular risk profile when choosing among migraine preventive therapies.